found a high consistency of mutation patterns between primary LC lesions and matched BM, which indicated that the effective treatment of primary LC may also be suitable for matched LCBM, such as the EGFR-TKI treatment for LCBM with sensitive EGFR mutations (43). The gene discussed is EGFR; the disease is laryngotracheoesophageal cleft.